NCT01745588View on ClinicalTrials.gov

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 3, 2025

Study Completion Date

September 3, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

PROCEDURE

stem cell

DRUG

Dexamethasone

DRUG

Clarithromycin

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

10604

Memorial Sloan Kettering West Harrison, Harrison

11040

North Shore LIJ, New Hyde Park

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

Weill Medical College of Cornell University, New York

SUNY Upstate Medical University, Syracuse

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

North Shore University Hospital

OTHER

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

State University of New York - Upstate Medical University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER